Literature DB >> 12393943

An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog.

F Markos1, B A Hennessy, M Fitzpatrick, J O'Sullivan, H M Snow.   

Abstract

The effectiveness of competitive peptide vasoactive intestinal polypeptide (VIP) receptor antagonists was evaluated on heart rate in the anaesthetized dog. Two specific antagonists, VIP (6-28) and [D-p-Cl-Phe(6), Leu(17)]-VIP, and a nonspecific antagonist, pituitary adenylate cyclase activating peptide fragment (6-27) (PACAP), were studied. VIP (6-28) and [D-p-Cl-Phe(6), Leu(17)]-VIP (100 microg i.c.) increased the heart rate, whereas PACAP (100 microg i.c.) reduced the baseline heart rate. All three shifted the VIP dose-response curve to the right by two- to threefold for 30 min. In conclusion, PACAP, VIP (6-28), and [D-p-Cl-Phe(6), Leu(17)]-VIP have a direct effect on the heart rate, are equally effective, and the effects last approximately 30 min in vivo. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393943     DOI: 10.1159/000065535

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  Neuropeptide-mediated calcium signaling in the suprachiasmatic nucleus network.

Authors:  Robert P Irwin; Charles N Allen
Journal:  Eur J Neurosci       Date:  2010-10-12       Impact factor: 3.386

2.  Vagal postganglionic origin of vasoactive intestinal polypeptide (VIP) mediating the vagal tachycardia.

Authors:  F Markos; H M Snow
Journal:  Eur J Appl Physiol       Date:  2006-08-09       Impact factor: 3.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.